Outlook Therapeutics - OTLK Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OTLK shares.
View OTLK analyst ratings or view top-rated stocks.

5 brokerages have issued 12-month price objectives for Outlook Therapeutics' shares. Their OTLK share price forecasts range from $4.00 to $7.00. On average, they expect the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 452.9% from the stock's current price.
View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts.

Outlook Therapeutics' stock was trading at $1.08 at the beginning of 2023. Since then, OTLK shares have decreased by 3.7% and is now trading at $1.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.
View our OTLK earnings forecast.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its quarterly earnings data on Tuesday, February, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.04.

Outlook Therapeutics shares reverse split before market open on Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 15th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX).

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

Outlook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.11%), Vista Finance LLC (0.11%), Lincoln National Corp (0.08%), Millennium Management LLC (0.07%), Bank of America Corp DE (0.06%) and Morgan Stanley (0.04%). Insiders that own company stock include C Russell Trenary III, Faisal Ghiath Sukhtian, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Randy H Thurman, Syntone Ventures Llc, Terry Dagnon and Yezan Munther Haddadin.
View institutional ownership trends.

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OTLK stock can currently be purchased for approximately $1.04.

Outlook Therapeutics (NASDAQ:OTLK) has a market capitalization of $266.93 million.

Outlook Therapeutics' mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.outlooktherapeutics.com. The company can be reached via phone at (609) 619-3990 or via email at jeremy@lifesciadvisors.com.